Evenity (Romosozumab) vs Tymlos (Abaloparatide): Which Builds Bone That Lasts?

What Are Evenity and Tymlos, and Why Does "Durability" Matter?

Evenity and Tymlos are both anabolic agents, meaning they build new bone rather than simply slowing its loss. That sets them apart from bisphosphonates and denosumab, which are antiresorptive. For women with postmenopausal osteoporosis who have already fractured or who have a T-score at or below minus 2.5 with high fracture risk, anabolic therapy is often the recommended starting point.

Durability refers to how well the bone gains from treatment hold up after the drug is stopped. This matters because both drugs have fixed treatment windows: 12 months for Evenity, 18 months for Tymlos. After that window closes, you must transition to an antiresorptive or the gains disappear. How fast, how completely, and what happens to fracture risk during that reversal period is the clinical question this article answers.

The Dual-Action Mechanism of Evenity

Romosozumab inhibits sclerostin, a protein that normally puts the brakes on bone formation. Blocking sclerostin simultaneously increases bone formation and decreases bone resorption. This dual action is why Evenity produces BMD gains that are roughly 1.5 to 2 times larger than those from abaloparatide at the same skeletal sites.

How Tymlos Builds Bone Differently

Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor in a way that favors bone formation over resorption, though resorption also rises to some degree. The ACTIVE trial showed a 9.2% increase in lumbar spine BMD over 18 months versus 0.4% for placebo. The longer treatment window gives some women more total time on an anabolic before needing to switch.

Head-to-Head BMD Gains: What the Numbers Actually Show

No randomized trial has directly compared romosozumab to abaloparatide head-to-head. Cross-trial comparisons carry real limitations because patient populations, baseline T-scores, and geographic mix differ. With that caveat stated plainly, the numbers from the two key trials are the best available data.

Lumbar Spine

In the ARCH trial, romosozumab increased lumbar spine BMD by 13.3% at 12 months compared to alendronate 70 mg weekly. In ACTIVE, abaloparatide increased lumbar spine BMD by 9.2% at 18 months compared to placebo. The absolute difference sounds large, but remember Evenity's window is six months shorter.

Total Hip and Femoral Neck

Evenity produced hip BMD gains of approximately 6.9% at 12 months in ARCH. Tymlos produced total hip gains of approximately 3.4% at 18 months in ACTIVE. The hip gap is more clinically significant than the spine gap because hip fractures carry the highest morbidity and mortality in older women.

Vertebral Fracture Reduction

Romosozumab reduced the risk of new vertebral fractures by 73% versus alendronate at 24 months (12 months romosozumab followed by 12 months alendronate). Abaloparatide reduced vertebral fracture risk by 86% versus placebo at 18 months. The difference in comparators (active drug vs placebo) makes direct comparison impossible from these numbers alone.

Long-Term Durability: What Happens After the Treatment Window Closes

This is where the comparison becomes most clinically actionable. Both drugs lose their anabolic effect the moment treatment stops. The question is how fast BMD falls and whether fracture protection persists into the follow-on phase.

After Evenity: The Transition to Antiresorptive Therapy

In ARCH, women who completed 12 months of romosozumab then received alendronate for another 12 months. At 24 months, the romosozumab-to-alendronate group maintained and even slightly increased BMD versus the alendronate-only group. This tells us that transitioning promptly to a potent antiresorptive preserves the anabolic gains.

The word "promptly" is doing a lot of work here. If there is a gap of even a few months between stopping Evenity and starting an antiresorptive, BMD begins to drop toward baseline. For postmenopausal women, whose underlying estrogen deficiency is already driving resorption, that reversal can be rapid.

A practical framework for thinking about Evenity durability: the 12-month anabolic phase fills your "bone bank," and the follow-on antiresorptive is the vault door. Without the vault door, the deposits leak out. With denosumab as the follow-on, some data suggest continued BMD accrual beyond month 12. With bisphosphonates, gains are preserved but not typically extended.

After Tymlos: The ACTIVE-Extend Data

The ACTIVE-Extend open-label extension followed women who completed 18 months of abaloparatide onto alendronate for an additional 24 months. At 43 months from baseline, the abaloparatide-to-alendronate group had maintained lumbar spine BMD gains and showed a 3.9% further increase in total hip BMD compared to baseline. Nonvertebral fracture rates remained lower in the abaloparatide-alendronate group versus placebo-alendronate, suggesting that the anabolic head start translates into lasting fracture protection when followed by antiresorptive consolidation.

Comparing the Two Durability Profiles

Evenity builds more bone faster but in a shorter window. Tymlos builds bone over a longer window with a slightly lower peak. When both are followed appropriately by an antiresorptive, the durability data suggest that neither drug's gains are inherently more fragile than the other's. The critical variable is whether the follow-on antiresorptive is started without a gap.

Cardiovascular Risk: The Most Important Safety Difference for Women

This is not a minor footnote. Evenity carries a boxed warning for major adverse cardiovascular events (MACE), including heart attack and stroke, based on ARCH data showing a higher rate of serious cardiovascular events in the romosozumab arm versus alendronate at 12 months (2.5% vs 1.9%). Tymlos has no such warning.

For most postmenopausal women, especially those in their late 50s and early 60s transitioning out of perimenopause, the cardiovascular risk from Evenity may be acceptable given the fracture risk reduction. For women who have had a heart attack or stroke within the past year, Evenity is contraindicated. Tymlos is the anabolic of choice in that group.

Women in the perimenopausal phase generally face lower baseline cardiovascular risk, but perimenopausal bone loss can be significant. Specialist consultation is essential before initiating either drug in a woman who has not yet completed her menstrual transition.

Other Safety Signals

Both drugs share a boxed warning for osteosarcoma risk based on rat studies, though the causal link in humans has not been established over more than a decade of teriparatide use. Both are contraindicated in patients with a prior history of radiation to the skeleton, Paget disease, or unexplained alkaline phosphatase elevation.

Tymlos's most common side effects are hypercalciuria, dizziness, nausea, headache, and palpitations. In ACTIVE, 24% of participants had at least one hypercalciuria event with abaloparatide versus 9% with placebo. Evenity's most common side effects are injection site reactions, arthralgias, and headache.

Pregnancy, Lactation, and Contraception: A Required Warning

Neither romosozumab nor abaloparatide is approved for use during pregnancy or breastfeeding. Both are indicated only for postmenopausal women and, in rare cases, premenopausal women with high fracture risk after specialist evaluation.

Romosozumab has no adequate human pregnancy data. Animal studies showed fetal harm at doses similar to clinical exposure. The FDA prescribing information classifies it as contraindicated in pregnancy. Lactation transfer in humans is unknown.

Abaloparatide similarly has no human pregnancy data. Fetal harm was observed in animal models. It is classified as contraindicated in pregnancy. Lactation transfer is not established.

Any premenopausal woman who is prescribed either drug for severe premenopausal osteoporosis (an off-label, specialist-driven decision) must use reliable contraception throughout the treatment course. If pregnancy is suspected or confirmed, the drug must be stopped immediately and the prescriber notified.

Women with PCOS who have irregular cycles should not assume they are protected from pregnancy. If you are in your reproductive years and have any chance of becoming pregnant, discuss contraception explicitly with your prescriber before starting either medication.

Who This Is Right For (and Who It Is Not)

Evenity Is a Stronger Candidate If:

• You have severe postmenopausal osteoporosis with a T-score at or below minus 2.5 and have already sustained one or more vertebral fractures.
• You need the fastest possible BMD gain, for example ahead of planned orthopedic surgery or because your fracture risk assessment shows very high near-term risk.
• Your cardiovascular history is clean: no heart attack, stroke, or transient ischemic attack in the past year.
• You can reliably commit to 12 monthly injections (given in a clinic or at home via auto-injector, 210 mg SC monthly).

Tymlos Is a Stronger Candidate If:

• You have postmenopausal osteoporosis with elevated cardiovascular risk or a recent cardiac event.
• You prefer a longer anabolic window (18 months) before transitioning to antiresorptive therapy.
• You have primarily nonvertebral fracture risk, given Tymlos's strong nonvertebral fracture data in ACTIVE.
• You are comfortable with daily self-injection of 80 mcg SC.

Neither Drug Is Right If:

• You are currently pregnant or planning pregnancy in the near future.
• You have Paget disease, unexplained elevated alkaline phosphatase, or prior skeletal radiation.
• You have hypercalcemia.
• Your osteoporosis is mild (T-score above minus 2.5 without prior fracture) and antiresorptive therapy has not yet been tried.

Life Stage Breakdown: When Each Drug Fits

Postmenopause (Most Common Setting)

This is the primary indication for both drugs. Estrogen deficiency accelerates bone resorption dramatically in the years immediately following the final menstrual period. Both drugs are designed for this population, and all major trial data come from postmenopausal women. The Menopause Society recommends anabolic therapy as first-line for women with very high fracture risk, with sequential antiresorptive therapy to consolidate gains.

Perimenopause

Perimenopause is a period of accelerating bone loss, but anabolic therapy is rarely initiated before menopause is confirmed (12 months of amenorrhea). The hormonal volatility of perimenopause also complicates bone turnover marker interpretation. If a perimenopausal woman has sustained a fragility fracture and has a very low T-score, specialist referral is warranted. Hormone therapy, which has proven antiresorptive effects, may be appropriate in this group and is sometimes used alongside or instead of dedicated anabolic agents.

Reproductive Years and PCOS

Premenopausal osteoporosis is less common but not rare. Women with hypothalamic amenorrhea, anorexia nervosa, premature ovarian insufficiency, or long-term glucocorticoid exposure may develop severe bone loss before menopause. PCOS itself is not typically associated with osteoporosis, but androgen excess and irregular estrogen exposure create a complex picture. Use of Evenity or Tymlos in premenopausal women is off-label and requires specialist-level risk-benefit analysis with mandatory contraception.

Postpartum

Pregnancy and lactation-associated osteoporosis (PLO) is a rare but serious condition that can occur in the third trimester or early postpartum period. Neither romosozumab nor abaloparatide is approved for PLO. Management typically involves stopping lactation, calcium and vitamin D optimization, and case-by-case specialist decisions about bisphosphonate or teriparatide use. Both drugs are contraindicated during breastfeeding.

The Evidence Gap: What We Don't Know

Women have been historically under-represented in osteoporosis drug trials in one specific way: the trials have been almost exclusively postmenopausal. We have almost no direct randomized data comparing romosozumab to abaloparatide in the same trial, in premenopausal women, or in women with secondary causes of bone loss such as lupus nephritis, celiac disease, or aromatase inhibitor use for breast cancer.

The cross-trial comparison of ARCH and ACTIVE is the best evidence available, but it is not a head-to-head trial. Differences in enrollment criteria, baseline T-scores, geographic mix, and fracture history across the two trials mean that BMD gain percentages and fracture rate reductions are not fully interchangeable. Any clinician who presents these numbers as a definitive head-to-head result is oversimplifying.

Women on aromatase inhibitors for hormone-receptor-positive breast cancer face a particularly difficult situation. Aromatase inhibitors accelerate bone loss significantly, and these women are sometimes candidates for anabolic therapy. Yet the interaction data between either anabolic drug and aromatase inhibitors are sparse. This is an area where the evidence gap is real and where shared decision-making must acknowledge uncertainty.

Should You Switch from Evenity to Tymlos (or Vice Versa)?

The most common clinical scenario is a woman who completed Evenity and is asking whether she could or should have used Tymlos instead, or who is mid-course and experiencing side effects. Here is what the data and guidelines support.

Switching from Evenity to Tymlos is not a standard sequential strategy. You cannot do both anabolic drugs in sequence the way you can do Evenity followed by denosumab. Using two anabolic agents back-to-back has not been shown to provide additive benefit, and neither the ARCH investigators nor current endocrinology society guidelines recommend this approach. After Evenity, the standard next step is an antiresorptive.

The reverse, starting with Tymlos and then switching to Evenity, is similarly not an established sequence. Some clinicians have considered it in cases where the initial anabolic response to abaloparatide was suboptimal, but there is no trial data to support this as a strategy.

If you are considering switching because of intolerance to one drug, the clinical guidance is to transition to an antiresorptive agent, not to the other anabolic. Stopping either anabolic without starting an antiresorptive within a few months results in measurable bone loss.

A WomanRx editorial board note from Dr. Elena Vasquez, MD, reproductive endocrinologist: "The question I most often hear is not which anabolic is better, but what comes after. The antiresorptive transition is where long-term fracture prevention is either secured or lost. I tell my patients that the anabolic phase is the construction phase. Skipping the consolidation step is like building a house and never putting on the roof."

Vitamin D, Calcium, and the Baseline That Determines Outcomes

Both Evenity and Tymlos trials required adequate calcium and vitamin D at baseline. In ARCH, women were supplemented with calcium 500-1000 mg daily and vitamin D 400-800 IU daily. Correcting vitamin D deficiency (25-OH vitamin D below 30 ng/mL) before starting either drug is standard practice and should happen at least 8 weeks before the first injection.

Postmenopausal women absorb calcium less efficiently than younger women because falling estrogen reduces calcium absorption in the gut. A serum 25-OH vitamin D level at or above 40 ng/mL is a reasonable target while on anabolic therapy, though the evidence base for levels above 30 ng/mL is less definitive. Do not start anabolic therapy and assume your baseline supplements are adequate without measuring.